Spondyloarthritis & psoriatic arthritis
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies
Authors' conclusion
Bimekizumab treatment resulted in sustained improvements in patient-reported symptoms and their impacts across the full disease spectrum of axSpA over 2 years
Study context
- Population
- Patients with axial spondyloarthritis (axSpA): non-radiographic (BE MOBILE 1) and radiographic (BE MOBILE 2)494 entered BE MOVING
- Participants
- 586 patients
Methodological detailsBE MOVING, 16-week double-blind placebo-controlled period, 36-week maintenance period, 494/586 (84.3%) entered BE MOVING at week 52
- BE MOVING
- 16-week double-blind placebo-controlled period
- 36-week maintenance period
- 494/586 (84.3%) entered BE MOVING at week 52
Primary result
As reported in the abstract
Change from baseline in patient-reported outcomes · week 104
- Total spinal pain (NRS 0-10)
- −4.3
- Nocturnal spinal pain
- −4.3
- Morning stiffness (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q5/6)
- −4.3
- Fatigue (BASDAI Q1)
- −3.4
- FACIT-Fatigue
- +9.9
- Sleep (MOS-Sleep Scale)
- +10.2
- Physical function (Bath Ankylosing Spondylitis Functional Index (BASFI))
- −2.9
- SF-36 physical component summary (PCS)
- +12.4
- Ankylosing Spondylitis Quality of Life (ASQoL)
- −5.6
Original publication
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies. RMD Open. Published 28 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →